<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-43316</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0094022</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology and life sciences</subject><subj-group><subject>Computational biology</subject><subj-group><subject>Genome analysis</subject><subj-group><subject>Genomic databases</subject><subject>Transcriptome analysis</subject></subj-group></subj-group></subj-group><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject></subj-group></subj-group><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Sequencing techniques</subject><subj-group><subject>Sequence analysis</subject><subj-group><subject>Sequence databases</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Carcinomas</subject><subj-group><subject>Thyroid carcinomas</subject><subj-group><subject>Follicular thyroid carcinoma</subject></subj-group></subj-group></subj-group><subj-group><subject>Endocrine tumors</subject></subj-group></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Identification of Thyroid Carcinoma Related Genes with mRMR and Shortest Path Approaches</article-title>
<alt-title alt-title-type="running-head">Thyroid Cancer mRMR</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Xu</surname><given-names>Yaping</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Deng</surname><given-names>Yue</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ji</surname><given-names>Zhenhua</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>Haibin</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>Yueyang</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Peng</surname><given-names>Hu</given-names></name><xref ref-type="aff" rid="aff1"/></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wu</surname><given-names>Jian</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Fan</surname><given-names>Jingping</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><addr-line>Department of Otolaryngology head and neck surgery, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Ranganathan</surname><given-names>Shoba</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>Macquarie University, Australia</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">jianwu2008@126.com</email> (JW); <email xlink:type="simple">fanjingp@163.com</email> (JF)</corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: JF. Performed the experiments: JW. Analyzed the data: YD ZJ HL YL HP. Wrote the paper: YX YD JW.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2014</year></pub-date>
<pub-date pub-type="epub"><day>9</day><month>4</month><year>2014</year></pub-date>
<volume>9</volume>
<issue>4</issue>
<elocation-id>e94022</elocation-id>
<history>
<date date-type="received"><day>22</day><month>10</month><year>2013</year></date>
<date date-type="accepted"><day>12</day><month>3</month><year>2014</year></date>
</history>
<permissions>
<copyright-year>2014</copyright-year>
<copyright-holder>Xu et al</copyright-holder><license xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract>
<p>Thyroid cancer is a malignant neoplasm originated from thyroid cells. It can be classified into papillary carcinomas (PTCs) and anaplastic carcinomas (ATCs). Although ATCs are in an very aggressive status and cause more death than PTCs, their difference is poorly understood at molecular level. In this study, we focus on the transcriptome difference among PTCs, ATCs and normal tissue from a published dataset including 45 normal tissues, 49 PTCs and 11 ATCs, by applying a machine learning method, maximum relevance minimum redundancy, and identified 9 genes (<italic>BCL2, MRPS31, ID4, RASAL2, DLG2, MY01B, ZBTB5, PRKCQ</italic> and <italic>PPP6C</italic>) and 1 miscRNA (miscellaneous RNA, <italic>LOC646736</italic>) as important candidates involved in the progression of thyroid cancer. We further identified the protein-protein interaction (PPI) sub network from the shortest paths among the 9 genes in a PPI network constructed based on STRING database. Our results may provide insights to the molecular mechanism of the progression of thyroid cancer.</p>
</abstract>
<funding-group><funding-statement>This work was funded by Foundation for Military Medicine, China (BWS11C035). The founders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="6"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Thyroid tumors include encapsulated benign tumors and carcinomas, and carcinomas can be classified into papillary carcinomas (PTC) and anaplastic carcinomas (ATC). Although frequency of ATC is low (&lt;5%), it is in a very aggressive status of thyroid carcinomas, responsible for about half of its death and its patients have a short survival time after diagnosis (6 month in average) <xref ref-type="bibr" rid="pone.0094022-Ain1">[1]</xref>. ATC is evolved from PTC, and they are found to share genetic alterations <xref ref-type="bibr" rid="pone.0094022-Smallridge1">[2]</xref>. However, limited studies reported their difference at transcriptome level <xref ref-type="bibr" rid="pone.0094022-Smallridge1">[2]</xref>–<xref ref-type="bibr" rid="pone.0094022-Hebrant1">[5]</xref>, resulting a lack of systematic analysis of its tumor evolution.</p>
<p>In order to bring insight into the progression of thyroid carcinomas at systems level, we adopted a two-step computational strategy <xref ref-type="bibr" rid="pone.0094022-Li1">[6]</xref>. By using an effective machine learning method – mRMR (maximum relevance, minimum redundancy), we first identify genes responsible for the progressing transcriptome difference among normal tissue, PTC and ATC using the mRNA microarray data from Hebrant <italic>et al.</italic>'s study <xref ref-type="bibr" rid="pone.0094022-Hebrant1">[5]</xref>. The machine learning method mRMR does not only identify genes with independent effect along, but also take the redundancy effect among genes selected into account. Additional to the pipeline used by Li et al. <xref ref-type="bibr" rid="pone.0094022-Li1">[6]</xref>, we applied different validation methods, such as leave-one-out validation, 10 fold cross validation and stratified 10 fold cross validation, to determine the number of genes which separate the three tissue status, due to one validation method along may provide biased information of prediction accuracy of the machine learning model. Second, we address the function of these genes at systems level by integrating known protein-protein interaction (PPI) from STRING database. A network of shortest paths among the genes from a background PPI network could be further revealed.</p>
</sec><sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2a">
<title>Transcriptome Array Dataset</title>
<p>We adopted the gene expression data of thyroid cancer from Hebrant <italic>et al</italic>.'s study <xref ref-type="bibr" rid="pone.0094022-Hebrant1">[5]</xref>, which include the transcriptome array data of 11 anaplastic thyroid carcinomas (ATC), 49 papillary thyroid carcinomas (PTC) and 45 normal thyroids (Normal) based on Affymetrix Human Genome U133 Plus 2.0 Array. This dataset was retrieved from NCBI Gene Expression Omnibus (GEO) with an accession number GSE33630. The array platform is with 54,675 probes corresponding to 20,283 protein coding genes. The array signals were normalized with RMA using the Affymetrix Bioconductor package. For the expression value of a gene, we used the average value of normalized signals of its corresponding probes.</p>
</sec><sec id="s2b">
<title>STRING PPI data</title>
<p>The PPI data was retrieved from STRING database (version 9.0) (<ext-link ext-link-type="uri" xlink:href="http://string.embl.de/" xlink:type="simple">http://string.embl.de/</ext-link>) <xref ref-type="bibr" rid="pone.0094022-Szklarczyk1">[7]</xref>. The PPI data includes both known and predicted protein interactions. We constructed a PPI network based on the STRING PPI data using a R package ‘igraph’ <xref ref-type="bibr" rid="pone.0094022-Csardi1">[8]</xref>. In the network, proteins are presented as nodes of the networks and edges corresponding to the protein-protein interactions.</p>
</sec><sec id="s2c">
<title>The mRMR algorithm</title>
<p>We used mRMR (maximum relevance minimum redundancy) method to define a gene set which can separate the three sample sets (ATC, PTC and Normal). The mRMR was first used in analyzing microarray data by Peng <italic>et al</italic>. <xref ref-type="bibr" rid="pone.0094022-Peng1">[9]</xref>. Its idea is to rank features according to their relevance to the target sample variable, and meanwhile take redundancy among the features into consideration. So genes in the selected gene set has the best trade-off between maximum relevance to phenotype and minimum redundancy within genes in the selected set.</p>
<p>Using mutual information (MI) defined using <xref ref-type="disp-formula" rid="pone.0094022.e001">equation (1</xref>), we quantified relevance as well as redundancy,<disp-formula id="pone.0094022.e001"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pone.0094022.e001" xlink:type="simple"/><label>(1)</label></disp-formula>where <italic>p(x, y)</italic> is a joint probabilistic density of vectors <italic>x</italic> and <italic>y</italic>, and <italic>p(x)</italic> and <italic>p(y)</italic> are marginal probabilistic densities.</p>
<p>Relevance <italic>D</italic> between a gene <italic>f</italic> and its target variable <italic>c</italic> is defined as,<disp-formula id="pone.0094022.e002"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pone.0094022.e002" xlink:type="simple"/><label>(2)</label></disp-formula></p>
<p>And redundancy <italic>R</italic> between gene <italic>f</italic> and genes in gene set <italic>T</italic> is defined as,<disp-formula id="pone.0094022.e003"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pone.0094022.e003" xlink:type="simple"/><label>(3)</label></disp-formula>where <italic>m</italic> is the number of genes in <italic>T</italic>. The trade-off between relevance and redundancy is obtained as follows,<disp-formula id="pone.0094022.e004"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pone.0094022.e004" xlink:type="simple"/><label>(4)</label></disp-formula></p>
<p>Repeating the above calculation a gene set is selected to distinguish target variables under mRMR condition with a given number <italic>N</italic> of genes.</p>
<p>Using incremental feature selection (IFS), the number <italic>N</italic> can be determined. Its idea is to compare prediction accuracy defined in the following selection among different <italic>N</italic>s, and choose the one with highest accuracy.</p>
</sec><sec id="s2d">
<title>Prediction of phenotypes</title>
<p>We used the widely used Nearest Neighbor Algorithm (NNA) to predict the target variable <xref ref-type="bibr" rid="pone.0094022-Friedman1">[10]</xref>. “Nearness” is calculated as follows,<disp-formula id="pone.0094022.e005"><graphic position="anchor" xlink:href="info:doi/10.1371/journal.pone.0094022.e005" xlink:type="simple"/><label>(5)</label></disp-formula>where <italic>x<sub>1</sub></italic> and <italic>x<sub>2</sub></italic> are two vectors of genes representing two samples. The smaller <italic>N(x1, x2)</italic> is, the more similar the two samples are <xref ref-type="bibr" rid="pone.0094022-Chou1">[11]</xref>, <xref ref-type="bibr" rid="pone.0094022-Chou2">[12]</xref>.</p>
</sec><sec id="s2e">
<title>Model Validation</title>
<p>In Li et al. 's study <xref ref-type="bibr" rid="pone.0094022-Li1">[6]</xref>., leave-one-out validation was applied to validate the prediction accuracy of the study. Although the advantages of this validation method is explain in some studies <xref ref-type="bibr" rid="pone.0094022-Li1">[6]</xref>, <xref ref-type="bibr" rid="pone.0094022-Li2">[13]</xref>, we noticed that there are other theoretical studies demonstrated there are bias in the estimation of accuracy in the leave-one-out validation in many circumstances <xref ref-type="bibr" rid="pone.0094022-Ambroise1">[14]</xref>, <xref ref-type="bibr" rid="pone.0094022-Kohavi1">[15]</xref>. In order to provide more information of the accuracy of the prediction model and to give an accurate estimation of the number of genes separate different tumor status, we applied two additional validation methods – 10 fold cross validation <xref ref-type="bibr" rid="pone.0094022-Ambroise1">[14]</xref> and stratified 10 fold cross validation because of the stratification of tumor status (normal, PTC and ATC) <xref ref-type="bibr" rid="pone.0094022-Kohavi1">[15]</xref>.</p>
</sec><sec id="s2f">
<title>Shortest paths tracing</title>
<p>Genes do not function only by itself, but also by its interaction with others as well as environmental factors. Protein-protein interaction (PPI) network would bring us insights into the comprehensive biological systems. We attempted to provide such insights by searching the shortest paths which link the genes selected using mRMR and IFS in PPI network constructed according to STRING PPI data. The shortest paths were estimated using Dijkstra's algorithm <xref ref-type="bibr" rid="pone.0094022-Dijkstra1">[16]</xref>.</p>
</sec><sec id="s2g">
<title>Enrichment analysis</title>
<p>GO (Gene Ontology) term enrichment and KEGG pathway enrichment were performed using DAVID tools <xref ref-type="bibr" rid="pone.0094022-Huang1">[17]</xref>. We estimated the <italic>P</italic> values, corrected <italic>P</italic> values with Benjamin multiple testing correction which controlled family-wide false discovery rate, and fold enrichment values for each functional or pathway terms.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Ten candidate genes identified by mRMR, NNA and IFS</title>
<p>On the basis of mRMR estimation, we tested the predictor of NNA described in the Materials and Methods section, with one feature, two features, … to 400 features. The result of IFS curve representing prediction accuracy estimated by leave-one-out, 10 fold and stratified 10 fod cross validation, compared with the number of features is shown in <xref ref-type="fig" rid="pone-0094022-g001">Figure 1</xref>. We noticed that although the estimation accuracies different among the three different methods, but the minimum number of genes required separating tumor status is approximately the same – about 9 or 10 (<xref ref-type="fig" rid="pone-0094022-g001">Figure 1</xref> and <xref ref-type="supplementary-material" rid="pone.0094022.s001">Table S1</xref>). We selected 10 genes to include more candidates for further analysis and studies, and the accuracy was 0.848, 0.857 and 0.877 for leave-one-out, 10 fold and stratified 10 fold cross validation separately. The top 10 genes selected using mRMR include 9 known genes (<italic>BCL2, MRPS31, ID4, RASAL2, DLG2, MY01B, ZBTB5, PRKCQ, PPP6C</italic>), and a miscRNA (miscellaneous RNA, <italic>LOC646736</italic>) (<xref ref-type="table" rid="pone-0094022-t001">Table 1</xref>). Interestingly, the 10 candidate genes have no overlap with the 9 differentially expression gene between ATC and PTC identified in the Hebrant <italic>et al</italic>.'s study. One of the possible reasons is that in our detection, we considered the variation in transcriptome differences in normal tissue, ATC and PTC together.</p>
<fig id="pone-0094022-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0094022.g001</object-id><label>Figure 1</label><caption>
<title>IFS curve of the classification of ATCs, PTCs and normal tissue samples.</title>
<p>The X-axis indicate the number of genes used for classification/prediction, and Y-axis is the prediction accuracies by NNA evaluated using leave-one-out (orange), 10 fold (green) and stratified 10 fold (blue) cross validation.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0094022.g001" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0094022-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0094022.t001</object-id><label>Table 1</label><caption>
<title>The 10 Genes selected using mRMR and IFS.</title>
</caption><alternatives><graphic id="pone-0094022-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0094022.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Gene Name</td>
<td align="left" rowspan="1" colspan="1">Entrez Gene ID</td>
<td align="left" rowspan="1" colspan="1">mRMR score</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">BCL2</td>
<td align="left" rowspan="1" colspan="1">596</td>
<td align="left" rowspan="1" colspan="1">1.09662945</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MRPS31</td>
<td align="left" rowspan="1" colspan="1">10240</td>
<td align="left" rowspan="1" colspan="1">0.222372096</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ID4</td>
<td align="left" rowspan="1" colspan="1">3400</td>
<td align="left" rowspan="1" colspan="1">0.32164204</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">RASAL2</td>
<td align="left" rowspan="1" colspan="1">9462</td>
<td align="left" rowspan="1" colspan="1">0.390513354</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">DLG2</td>
<td align="left" rowspan="1" colspan="1">1740</td>
<td align="left" rowspan="1" colspan="1">0.334284222</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">MY01B</td>
<td align="left" rowspan="1" colspan="1">4430</td>
<td align="left" rowspan="1" colspan="1">0.354486787</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ZBTB5</td>
<td align="left" rowspan="1" colspan="1">9925</td>
<td align="left" rowspan="1" colspan="1">0.384452316</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">LOC646736</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">0.339571667</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PRKCQ</td>
<td align="left" rowspan="1" colspan="1">5588</td>
<td align="left" rowspan="1" colspan="1">0.359410448</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">PPP6C</td>
<td align="left" rowspan="1" colspan="1">5537</td>
<td align="left" rowspan="1" colspan="1">0.340892868</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s3b">
<title>Shortest path genes</title>
<p>We constructed an undirected network based on PPI data from STRING using ‘igraph’ <xref ref-type="bibr" rid="pone.0094022-Csardi1">[8]</xref>. Then we traced shortest path between each pair of two genes from the 9 candidate genes identified using mRMR, in the PPI network using Dijkstra's algorithm <xref ref-type="bibr" rid="pone.0094022-Dijkstra1">[16]</xref>. There are 16 genes located on the shortest path among the 9 candidate genes, and we presented them according to their network betweenness in the shortest paths composed sub-PPI network (<xref ref-type="table" rid="pone-0094022-t002">Table 2</xref> and <xref ref-type="fig" rid="pone-0094022-g002">Figure 2</xref>).</p>
<fig id="pone-0094022-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0094022.g002</object-id><label>Figure 2</label><caption>
<title>17 shortest paths genes among the 9 genes identified with mRMR methods.</title>
<p>We identified 17 genes located on the shortest paths of STRING PPI network among the 9 mRMR identified genes. Genes in blue are those identified with mRMR methods, and genes in red are located on their shortest paths. The network is constructed based on STRING PPI data.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0094022.g002" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0094022-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0094022.t002</object-id><label>Table 2</label><caption>
<title>Proteins selected on the shortest paths among the mRMR selected proteins.</title>
</caption><alternatives><graphic id="pone-0094022-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0094022.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Ensembl Gene ID</td>
<td align="left" rowspan="1" colspan="1">Ensembl Protein ID</td>
<td align="left" rowspan="1" colspan="1">Associated Gene Name</td>
<td align="left" rowspan="1" colspan="1">betweenness</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000091831</td>
<td align="left" rowspan="1" colspan="1">ENSP00000206249</td>
<td align="left" rowspan="1" colspan="1">ESR1</td>
<td align="left" rowspan="1" colspan="1">5</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000010610</td>
<td align="left" rowspan="1" colspan="1">ENSP00000011653</td>
<td align="left" rowspan="1" colspan="1">CD4</td>
<td align="left" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000150991</td>
<td align="left" rowspan="1" colspan="1">ENSP00000344818</td>
<td align="left" rowspan="1" colspan="1">UBC</td>
<td align="left" rowspan="1" colspan="1">4</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000143933</td>
<td align="left" rowspan="1" colspan="1">ENSP00000272298</td>
<td align="left" rowspan="1" colspan="1">CALM2</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000132170</td>
<td align="left" rowspan="1" colspan="1">ENSP00000287820</td>
<td align="left" rowspan="1" colspan="1">PPARG</td>
<td align="left" rowspan="1" colspan="1">3</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000029363</td>
<td align="left" rowspan="1" colspan="1">ENSP00000031135</td>
<td align="left" rowspan="1" colspan="1">BCLAF1</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000050820</td>
<td align="left" rowspan="1" colspan="1">ENSP00000162330</td>
<td align="left" rowspan="1" colspan="1">BCAR1</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000100906</td>
<td align="left" rowspan="1" colspan="1">ENSP00000216797</td>
<td align="left" rowspan="1" colspan="1">NFKBIA</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000106588</td>
<td align="left" rowspan="1" colspan="1">ENSP00000223321</td>
<td align="left" rowspan="1" colspan="1">PSMA2</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000112365</td>
<td align="left" rowspan="1" colspan="1">ENSP00000230122</td>
<td align="left" rowspan="1" colspan="1">ZBTB24</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000115956</td>
<td align="left" rowspan="1" colspan="1">ENSP00000234313</td>
<td align="left" rowspan="1" colspan="1">PLEK</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000141510</td>
<td align="left" rowspan="1" colspan="1">ENSP00000269305</td>
<td align="left" rowspan="1" colspan="1">TP53</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000204519</td>
<td align="left" rowspan="1" colspan="1">ENSP00000282296</td>
<td align="left" rowspan="1" colspan="1">ZNF551</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000154342</td>
<td align="left" rowspan="1" colspan="1">ENSP00000284523</td>
<td align="left" rowspan="1" colspan="1">WNT3A</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000158092</td>
<td align="left" rowspan="1" colspan="1">ENSP00000288986</td>
<td align="left" rowspan="1" colspan="1">NCK1</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000147044</td>
<td align="left" rowspan="1" colspan="1">ENSP00000367408</td>
<td align="left" rowspan="1" colspan="1">CASK</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ENSG00000074071</td>
<td align="left" rowspan="1" colspan="1">ENSP00000380531</td>
<td align="left" rowspan="1" colspan="1">MRPS34</td>
<td align="left" rowspan="1" colspan="1">2</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s3c">
<title>Enrichment of the 9 candidate genes and shortest paths genes</title>
<p>Using DAVID tools <xref ref-type="bibr" rid="pone.0094022-Huang1">[17]</xref>, we analyzed the functional enrichment of the 9 candidate genes together with 16 shortest path genes in KEGG pathway and GO term separately. For KEGG enrichment, the 25 genes are enriched in 7 KEGG pathways listed with their <italic>P</italic> value and <italic>fold enrichment</italic> value in <xref ref-type="table" rid="pone-0094022-t003">Table 3</xref>. Interestingly, we found most of these pathways are important pathways related with cancer, such as T cell receptor signaling pathway, apoptosis, pathways in cancer, small cell lung cancer, prostate cancer, and thyroid cancer. T Cell Receptor (TCR) activation promotes several important signals that determine cell fate through regulating cytokine production, cell survival, proliferation, and differentiation. And T cells are especially important in cell-mediated immunity, which is the defense against tumor cells. More detailed functions of TCR in cancer is reviewed in Reference <xref ref-type="bibr" rid="pone.0094022-Cronin1">[18]</xref>. Moreover, thyroid cancer pathway was also found enriched by the set of the 25 genes. For GO term enrichment, 262 GO terms are enriched (<xref ref-type="supplementary-material" rid="pone.0094022.s002">Table S2</xref>). Several of them are related with cancer progression, like GO:0042127 regulation of cell proliferation, GO:0042980 regulation of apoptosis and GO:0043067 regulation of programmed cell death. These results provide circumstantial evidence supporting our data analysis pipeline.</p>
<table-wrap id="pone-0094022-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0094022.t003</object-id><label>Table 3</label><caption>
<title>KEGG pathway enrichment of the 25 genes selected on the shortest paths.</title>
</caption><alternatives><graphic id="pone-0094022-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0094022.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Term</td>
<td align="left" rowspan="1" colspan="1">Gene Count</td>
<td align="left" rowspan="1" colspan="1"><italic>P</italic> Value</td>
<td align="left" rowspan="1" colspan="1">Fold Enrichment</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">T cell receptor signaling pathway</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.002282004</td>
<td align="left" rowspan="1" colspan="1">13.45238095</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Neurotrophin signaling pathway</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.003385035</td>
<td align="left" rowspan="1" colspan="1">11.71658986</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Pathways in cancer</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.007626354</td>
<td align="left" rowspan="1" colspan="1">5.536803136</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Small cell lung cancer</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">0.018690317</td>
<td align="left" rowspan="1" colspan="1">12.97193878</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Apoptosis</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">0.019971101</td>
<td align="left" rowspan="1" colspan="1">12.52463054</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Prostate cancer</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">0.02084525</td>
<td align="left" rowspan="1" colspan="1">12.24317817</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Thyroid cancer</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.071736805</td>
<td align="left" rowspan="1" colspan="1">25.04926108</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec></sec><sec id="s4">
<title>Discussion</title>
<sec id="s4a">
<title>Genes identified by mRMR and IFS</title>
<p>We identified 9 genes, <italic>BCL2, MRPS31, ID4, RASAL2, DLG2, MY01B, ZBTB5, PRKCQ</italic> and <italic>PPP6C</italic>, and a miscRNA <italic>LOC646736</italic> related with thyroid carcinoma in this study. Many of them are previously known important genes with thyroid development or cancer progression.</p>
<p><italic>BCL2</italic>, B-cell CLL/lymphoma 2, is a protein coding gene preventing cell apoptosis, and found in many Eukaryotic species. In our mRMR results, it has the highest mRMR score (1.097), suggesting it is the most important feature to separate ATC, PTC and normal tissues. Damage to BCL2 has been identified as a cause of a number of cancers, including ovarian <xref ref-type="bibr" rid="pone.0094022-Heubner1">[19]</xref>, breast <xref ref-type="bibr" rid="pone.0094022-Bachmann1">[20]</xref>, prostate <xref ref-type="bibr" rid="pone.0094022-Bachmann2">[21]</xref>, chronic lymphocytic leukemia <xref ref-type="bibr" rid="pone.0094022-Rossi1">[22]</xref>. It has also been found to be differentially expressed between PTCs and normal tissues <xref ref-type="bibr" rid="pone.0094022-Aksoy1">[23]</xref>, and genetic variants in BCL2 could contribute to the risk of thyroid cancer <xref ref-type="bibr" rid="pone.0094022-Eun1">[24]</xref>.</p>
<p>Inhibitor of DNA binding/Inhibitor of differentiation 4 (<italic>ID4</italic>) is a critical factor for cell proliferation and differentiation in normal vertebrate development <xref ref-type="bibr" rid="pone.0094022-Noetzel1">[25]</xref>. Its protein belongs to a family of helix-loop-helix (HLH) proteins (ld1, ld2, ld3 and ld4). ID proteins contain a HLH domain enabling interaction with other basic HLH (bHLH)-proteins, and act as dominant negative inhibitors of gene transcription <xref ref-type="bibr" rid="pone.0094022-Deleu1">[26]</xref>. Family members of <italic>ID</italic> genes have critical row in the tumor genesis of thyroid cancer. For example, <italic>ID1</italic> regulates growth and differentiation in thyroid cancer cells <xref ref-type="bibr" rid="pone.0094022-Kebebew1">[27]</xref>, and <italic>ID3</italic> was also identified as an early response protein and tumor marker for thyroid carcinomas <xref ref-type="bibr" rid="pone.0094022-Deleu1">[26]</xref>. <italic>ID4</italic> is most recently discovered member of <italic>ID</italic> genes, mainly express in thyroid and several other tissues <xref ref-type="bibr" rid="pone.0094022-Rigolet1">[28]</xref>, and a previous study has already reported it as a marker in breast cancer <xref ref-type="bibr" rid="pone.0094022-Noetzel1">[25]</xref>.</p>
</sec><sec id="s4b">
<title>Genes identified on PPI shortest paths</title>
<p><italic>ESR1</italic>, EStrogen Receptor 1, is the gene with the largest betweenness in the PPI network of shortest paths. It encodes estrogen receptor alpha (ERα), which mediates interaction between estrogens and its target sites together with ERβ. ERα and ERβ are both expressed in thyroid cancer cells, and the proliferation of thyroid cancer cells is promoted by an ERα agonist and reduced by enhanced expression of ERβ or by an ERβ agonist <xref ref-type="bibr" rid="pone.0094022-Chen1">[29]</xref>. Polymorphisms in <italic>ESR</italic> are also involved in tumor oncogenesis in several tissues (e.g. breast, prostate, ovary and thyroid), and may alter responsiveness of the tissues to estrogens <xref ref-type="bibr" rid="pone.0094022-Fujimoto1">[30]</xref>–<xref ref-type="bibr" rid="pone.0094022-Rebai1">[33]</xref>.</p>
<p><italic>PPARG</italic>, peroxisome proliferator-activated receptor gamma, encodes a member of the peroxisome proliferator-activated receptor (PPAR) subfamily of nuclear receptors. It is a regulator of adipocyte differentiation, and has been found in the pathology of numerous disease. Alterations of PPARG have been discovered in a large number of thyroid cancer samples, such as PAX8/PPARG fusion oncogene in follicular thyroid carcinoma and PTCs <xref ref-type="bibr" rid="pone.0094022-LeemanNeill1">[34]</xref>–<xref ref-type="bibr" rid="pone.0094022-Nikiforova1">[37]</xref>, and another PPARG agonist (RS54444) in ATCs <xref ref-type="bibr" rid="pone.0094022-Copland1">[38]</xref>.</p>
</sec></sec><sec id="s5">
<title>Conclusion</title>
<p>In this study, we focused on transcriptome of the progression of thyroid cancer, by applying a machine learning methods to identify candidate genes separating three status of thyroid, normal, PTC and ATC. The transcriptome data includes from 11 ATCs, 49 PTCs and 45 normal tissues. We identified 9 genes (<italic>BCL2, MRPS31, ID4, RASAL2, DLG2, MY01B, ZBTB5, PRKCQ</italic> and <italic>PPP6C</italic>) and a miscRNA (<italic>LOC646736</italic>) related with thyroid cancer progression, additional to the genes identified previously <xref ref-type="bibr" rid="pone.0094022-Hebrant1">[5]</xref>. We further revealed the PPI network of the proteins coded by these genes by estimating the shortest path of the interactions based on a background PPI network constructed based on SRING database. Our results may provide important insights to understand the mechanism of the thyroid cancer progression at transcriptome level.</p>
</sec><sec id="s6">
<title>Supporting Information</title>
<supplementary-material id="pone.0094022.s001" mimetype="application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" xlink:href="info:doi/10.1371/journal.pone.0094022.s001" position="float" xlink:type="simple"><label>Table S1</label><caption>
<p>Prediction accuracy of three validation methods.</p>
<p>(XLSX)</p>
</caption></supplementary-material><supplementary-material id="pone.0094022.s002" xlink:href="info:doi/10.1371/journal.pone.0094022.s002" mimetype="text/plain" position="float" xlink:type="simple"><label>Table S2</label><caption>
<p>GO enrichment of the 25 genes on the shortest paths.</p>
<p>(TXT)</p>
</caption></supplementary-material></sec></body>
<back>
<ack>
<p>Thanks to Hongqiang Wu (Biotree Bio-technology Co., Ltd., Shanghai, China) for providing helps in data analysis, and we also very appreciate the useful comments and suggestions from the reviewers.</p>
</ack>
<ref-list>
<title>References</title>
<ref id="pone.0094022-Ain1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ain</surname><given-names>KB</given-names></name> (<year>1999</year>) <article-title>Anaplastic thyroid carcinoma: A therapeutic challenge</article-title>. <source>Seminars in Surgical Oncology</source> <volume>16</volume>: <fpage>64</fpage>–<lpage>69</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Smallridge1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Smallridge</surname><given-names>RC</given-names></name>, <name name-style="western"><surname>Marlow</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Copland</surname><given-names>JA</given-names></name> (<year>2009</year>) <article-title>Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies</article-title>. <source>Endocrine-Related Cancer</source> <volume>16</volume>: <fpage>17</fpage>–<lpage>44</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-MonteroConde1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Montero-Conde</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Martin-Campos</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Lerma</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gimenez</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Martinez-Guitarte</surname><given-names>JL</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Molecular profiling related to poor prognosis in thyroid carcinoma. Combining gene expression data and biological information</article-title>. <source>Oncogene</source> <volume>27</volume>: <fpage>1554</fpage>–<lpage>1561</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Salvatore1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Salvatore</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Nappi</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Salerno</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Garbi</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma</article-title>. <source>Cancer Research</source> <volume>67</volume>: <fpage>10148</fpage>–<lpage>10158</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Hebrant1"><label>5</label>
<mixed-citation publication-type="other" xlink:type="simple">Hebrant A, Dom G, Dewaele M, Andry G, Tresallet C, et al. (2012) mRNA Expression in Papillary and Anaplastic Thyroid Carcinoma: Molecular Anatomy of a Killing Switch. Plos One 7.</mixed-citation>
</ref>
<ref id="pone.0094022-Li1"><label>6</label>
<mixed-citation publication-type="other" xlink:type="simple">Li B-Q, Huang T, Liu L, Cai Y-D, Chou K-C (2012) Identification of Colorectal Cancer Related Genes with mRMR and Shortest Path in Protein-Protein Interaction Network. Plos One 7.</mixed-citation>
</ref>
<ref id="pone.0094022-Szklarczyk1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Szklarczyk</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Franceschini</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kuhn</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Simonovic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>A</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored</article-title>. <source>Nucleic Acids Research</source> <volume>39</volume>: <fpage>D561</fpage>–<lpage>D568</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Csardi1"><label>8</label>
<mixed-citation publication-type="other" xlink:type="simple">Csardi G, Nepusz T (2006) The igraph software package for complex network research. InterJounal Complex Systems: 1695.</mixed-citation>
</ref>
<ref id="pone.0094022-Peng1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peng</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Long</surname><given-names>FH</given-names></name>, <name name-style="western"><surname>Ding</surname><given-names>C</given-names></name> (<year>2005</year>) <article-title>Feature selection based on mutual information: Criteria of max-dependency, max-relevance, and min-redundancy</article-title>. <source>Ieee Transactions on Pattern Analysis and Machine Intelligence</source> <volume>27</volume>: <fpage>1226</fpage>–<lpage>1238</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Friedman1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Friedman</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Baskett</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Shustek</surname><given-names>LJ</given-names></name> (<year>1975</year>) <article-title>An Algorithm for Finding Nearest Neighbors</article-title>. <source>Computers, IEEE Transactions on</source> <volume>C-24</volume>: <fpage>1000</fpage>–<lpage>1006</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Chou1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chou</surname><given-names>K-C</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>H-B</given-names></name> (<year>2006</year>) <article-title>Predicting eukaryotic protein subcellular location by fusing optimized evidence-theoretic K-Nearest Neighbor classifiers</article-title>. <source>Journal of Proteome Research</source> <volume>5</volume>: <fpage>1888</fpage>–<lpage>1897</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Chou2"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chou</surname><given-names>K-C</given-names></name> (<year>2011</year>) <article-title>Some remarks on protein attribute prediction and pseudo amino acid composition</article-title>. <source>Journal of Theoretical Biology</source> <volume>273</volume>: <fpage>236</fpage>–<lpage>247</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Li2"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname><given-names>B-Q</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>L-L</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>K-Y</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>Y-D</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Prediction of Protein Domain with mRMR Feature Selection and Analysis</article-title>. <source>PLoS ONE</source> <volume>7</volume>: <fpage>e39308</fpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Ambroise1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ambroise</surname><given-names>C</given-names></name>, <name name-style="western"><surname>McLachlan</surname><given-names>GJ</given-names></name> (<year>2002</year>) <article-title>Selection bias in gene extraction on the basis of microarray gene-expression data</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> <volume>99</volume>: <fpage>6562</fpage>–<lpage>6566</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Kohavi1"><label>15</label>
<mixed-citation publication-type="other" xlink:type="simple">Kohavi R (1995) A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the 14th international joint conference on Artificial intelligence- <volume>Volume 2.</volume> Montreal, Quebec, Canada: Morgan Kaufmann Publishers Inc. pp. 1137–1143.</mixed-citation>
</ref>
<ref id="pone.0094022-Dijkstra1"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dijkstra</surname><given-names>E</given-names></name> (<year>1959</year>) <article-title>A note on two problems in connection with graphs</article-title>. <source>Numerische Mathematik</source> <volume>1</volume>: <fpage>269</fpage>–<lpage>271</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Huang1"><label>17</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Sherman</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Lempicki</surname><given-names>RA</given-names></name> (<year>2009</year>) <article-title>Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources</article-title>. <source>Nature Protocols</source> <volume>4</volume>: <fpage>44</fpage>–<lpage>57</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Cronin1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cronin</surname><given-names>SJF</given-names></name>, <name name-style="western"><surname>Penninger</surname><given-names>JM</given-names></name> (<year>2007</year>) <article-title>From T-cell activation signals to signaling control of anti-cancer immunity</article-title>. <source>Immunological Reviews</source> <volume>220</volume>: <fpage>151</fpage>–<lpage>168</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Heubner1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Heubner</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wimberger</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Otterbach</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Kasimir-Bauer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Siffert</surname><given-names>W</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Association of the AA genotype of the BCL2 (-938C&gt;A) promoter polymorphism with better survival in ovarian cancer</article-title>. <source>Int J Biol Markers</source> <volume>24</volume>: <fpage>223</fpage>–<lpage>229</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Bachmann1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bachmann</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Otterbach</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Callies</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Nuckel</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bau</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>The AA genotype of the regulatory BCL2 promoter polymorphism (938C&gt;A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients</article-title>. <source>Clin Cancer Res</source> <volume>13</volume>: <fpage>5790</fpage>–<lpage>5797</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Bachmann2"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bachmann</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Heukamp</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Schmitz</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Hilburn</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Kahl</surname><given-names>P</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Regulatory BCL2 promoter polymorphism (-938C&gt;A) is associated with adverse outcome in patients with prostate carcinoma</article-title>. <source>Int J Cancer</source> <volume>129</volume>: <fpage>2390</fpage>–<lpage>2399</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Rossi1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rossi</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Rasi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Capello</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Gaidano</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>Prognostic assessment of BCL2-938C&gt;A polymorphism in chronic lymphocytic leukemia</article-title>. <source>Blood</source> <volume>111</volume>: <fpage>466</fpage>–<lpage>468</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Aksoy1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aksoy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Giles</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Kapran</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Terzioglu</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tezelman</surname><given-names>S</given-names></name> (<year>2005</year>) <article-title>Expression of bcl-2 in papillary thyroid cancers and its prognostic value</article-title>. <source>Acta Chir Belg</source> <volume>105</volume>: <fpage>644</fpage>–<lpage>648</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Eun1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eun</surname><given-names>YG</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>IK</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>HK</given-names></name>, <name name-style="western"><surname>Kwon</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>A Polymorphism (rs1801018, Thr7Thr) of BCL2 is Associated with Papillary Thyroid Cancer in Korean Population</article-title>. <source>Clin Exp Otorhinolaryngol</source> <volume>4</volume>: <fpage>149</fpage>–<lpage>154</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Noetzel1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Noetzel</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Veeck</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Niederacher</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Galm</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Horn</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer</article-title>. <source>BMC Cancer</source> <volume>8</volume>: <fpage>154</fpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Deleu1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Deleu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Savonet</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Behrends</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Dumont</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Maenhaut</surname><given-names>C</given-names></name> (<year>2002</year>) <article-title>Study of gene expression in thyrotropin-stimulated thyroid cells by cDNA expression array: ID3 transcription modulating factor as an early response protein and tumor marker in thyroid carcinomas</article-title>. <source>Exp Cell Res</source> <volume>279</volume>: <fpage>62</fpage>–<lpage>70</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Kebebew1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kebebew</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Treseler</surname><given-names>PA</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>OH</given-names></name>, <name name-style="western"><surname>Duh</surname><given-names>QY</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Id1 gene expression is up-regulated in hyperplastic and neoplastic thyroid tissue and regulates growth and differentiation in thyroid cancer cells</article-title>. <source>J Clin Endocrinol Metab</source> <volume>89</volume>: <fpage>6105</fpage>–<lpage>6111</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Rigolet1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rigolet</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Rich</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Gross-Morand</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Molina-Gomes</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Viegas-Pequignot</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>1998</year>) <article-title>cDNA cloning, tissue distribution and chromosomal localization of the human ID4 gene</article-title>. <source>DNA Res</source> <volume>5</volume>: <fpage>309</fpage>–<lpage>313</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Chen1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>GG</given-names></name>, <name name-style="western"><surname>Vlantis</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>van Hasselt</surname><given-names>CA</given-names></name> (<year>2008</year>) <article-title>Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer</article-title>. <source>Curr Cancer Drug Targets</source> <volume>8</volume>: <fpage>367</fpage>–<lpage>377</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Fujimoto1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fujimoto</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hirose</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ichigo</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Sakaguchi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Tamaya</surname><given-names>T</given-names></name> (<year>1998</year>) <article-title>DNA polymorphism in B-domain of the estrogen receptor-alpha among Japanese women</article-title>. <source>Steroids</source> <volume>63</volume>: <fpage>146</fpage>–<lpage>148</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Lehrer1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lehrer</surname><given-names>SP</given-names></name>, <name name-style="western"><surname>Schmutzler</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>Rabin</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Schachter</surname><given-names>BS</given-names></name> (<year>1993</year>) <article-title>An estrogen receptor genetic polymorphism and a history of spontaneous abortion—correlation in women with estrogen receptor positive breast cancer but not in women with estrogen receptor negative breast cancer or in women without cancer</article-title>. <source>Breast Cancer Res Treat</source> <volume>26</volume>: <fpage>175</fpage>–<lpage>180</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Massart1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Massart</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Becherini</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gennari</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Facchini</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Genazzani</surname><given-names>AR</given-names></name>, <etal>et al</etal>. (<year>2001</year>) <article-title>Genotype distribution of estrogen receptor-alpha gene polymorphisms in Italian women with surgical uterine leiomyomas</article-title>. <source>Fertil Steril</source> <volume>75</volume>: <fpage>567</fpage>–<lpage>570</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Rebai1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rebai</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kallel</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Charfeddine</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hamza</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Guermazi</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk</article-title>. <source>J Recept Signal Transduct Res</source> <volume>29</volume>: <fpage>113</fpage>–<lpage>118</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-LeemanNeill1"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Leeman-Neill</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Brenner</surname><given-names>AV</given-names></name>, <name name-style="western"><surname>Little</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Bogdanova</surname><given-names>TI</given-names></name>, <name name-style="western"><surname>Hatch</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>RET/PTC and PAX8/PPARgamma chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics</article-title>. <source>Cancer</source> <volume>119</volume>: <fpage>1792</fpage>–<lpage>1799</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-McIver1"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>McIver</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Grebe</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Eberhardt</surname><given-names>NL</given-names></name> (<year>2004</year>) <article-title>The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma</article-title>. <source>Curr Drug Targets Immune Endocr Metabol Disord</source> <volume>4</volume>: <fpage>221</fpage>–<lpage>234</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Eberhardt1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Eberhardt</surname><given-names>NL</given-names></name>, <name name-style="western"><surname>Grebe</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>McIver</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Reddi</surname><given-names>HV</given-names></name> (<year>2010</year>) <article-title>The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer</article-title>. <source>Mol Cell Endocrinol</source> <volume>321</volume>: <fpage>50</fpage>–<lpage>56</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Nikiforova1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nikiforova</surname><given-names>MN</given-names></name>, <name name-style="western"><surname>Lynch</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Biddinger</surname><given-names>PW</given-names></name>, <name name-style="western"><surname>Alexander</surname><given-names>EK</given-names></name>, <name name-style="western"><surname>Dorn</surname><given-names>GW</given-names><suffix>2nd</suffix></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma</article-title>. <source>J Clin Endocrinol Metab</source> <volume>88</volume>: <fpage>2318</fpage>–<lpage>2326</lpage>.</mixed-citation>
</ref>
<ref id="pone.0094022-Copland1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Copland</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Marlow</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Kurakata</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fujiwara</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>AK</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1</article-title>. <source>Oncogene</source> <volume>25</volume>: <fpage>2304</fpage>–<lpage>2317</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>